On Monday, Sony Corp (ADR) (NYSE:SNE)’s shares inclined 0.20% to $25.46.
Technicolor and Sony Corporation (SNE) declared a joint patent licensing program for digital television (DTV) and computer display monitor (CDM). Technicolor will be the exclusive licensing agent of the combined portfolio that covers DTV and CDM. The license is offered for the convenience of both existing and new licensees, enabling them to obtain a single license as an alternative to negotiating separate licenses.
Technicolor is constantly investing in research and development in technology areas that are pervasively adopted in DTV and CDM, counting video and audio compression, high dynamic range, wide color gamut, user interface and other display technologies.
Sony, as a key player in the consumer electronics industry, has invested substantially in research and development of television, and has created a noteworthy portfolio that covers a wide array of DTV and CDM relevant technologies.
Sony Corporation designs, develops, manufactures, and sells electronic equipment, instruments, and devices for consumer, professional, and industrial markets worldwide. It offers LCD televisions; Blu-ray disc players and recorders, home audio, headphones, and memory-based portable audio devices; compact digital, interchangeable single-lens, and video cameras; professional solutions, such as broadcast- and professional-use products; and personal computers.
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)’s shares dropped -4.72% to $16.77.
Aegerion Pharmaceuticals, Inc. (AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, has designated Donald K. Stern, Esq., to its Board of Directors, effective right away. Mr. Stern will serve as a Class III director and will be up for reelection to the Board of Directors in 2016.
Mr. Stern is Managing Director of Corporate Monitoring & Consulting Services at Associated Monitors Inc., a consulting firm providing independent integrity monitoring services and compliance services across a wide range of regulated industries and professions. He is also Of Counsel to Yurko, Salvesen, & Remz, PC, a boutique litigation law firm in Boston.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products comprise JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments, counting low-density lipoprotein, low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia (HoFH); and LOJUXTA (lomitapide) hard capsule used as a treatment for HoFH in adults.
At the end of Monday’s trade, Biocept Inc (NASDAQ:BIOC)‘s shares surged 8.66% to $2.51.
Biocept, Inc. (BIOC), a molecular diagnostics company commercializing and developing assays for liquid biopsies to improve the detection and treatment of cancer, declares additional agreements with preferred provider organizations (PPOs). Stratose, Inc. and Galaxy Health Network (GHN) members will now have network access to Biocept’s proprietary non-invasive liquid biopsy testing. With these new agreements, which cover over 12 million members, about 31 million Americans have coverage for Biocept’s blood-based liquid biopsy testing through their healthcare plans.
Stratose maintains one of the largest directly managed PPO netoperates in the U.S., counting more than 850,000 direct and associate medical, dental and workers’ compensation provider contracts.
GHN comprises a network of more than 400,000 directly contracted physicians, facilities and hospitals.
Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company’s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors.
Ecolab Inc. (NYSE:ECL), ended its Monday’s trading session with 0.16% gain, and closed at $112.73.
Ecolab Inc., the global leader in water, hygiene and energy technology and services, has been named to the 2015 Dow Jones Sustainability Indices (DJSI) North America index.
The annual Dow Jones Sustainability Indices are based on a thorough analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk administration, branding, climate change mitigation, supply chain standards and labor practices.
Launched in 1999, the DJSI track the financial performance of the leading sustainability-driven companies worldwide. The indices serve as benchmarks for investors who integrate sustainability considerations into their portfolios, and provide an effective engagement platform for companies who want to adopt sustainable best practices.
Ecolab Inc. provides water, hygiene, and energy technologies and services for customers worldwide. The company operates in four segments: Global Industrial, Global Institutional, Global Energy, and Other.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
